These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 14680414

  • 1. Relapse and rehospitalization: comparing oral and depot antipsychotics.
    Schooler NR.
    J Clin Psychiatry; 2003; 64 Suppl 16():14-7. PubMed ID: 14680414
    [Abstract] [Full Text] [Related]

  • 2. Review of treatments that can ameliorate nonadherence in patients with schizophrenia.
    Kane JM.
    J Clin Psychiatry; 2006; 67 Suppl 5():9-14. PubMed ID: 16822091
    [Abstract] [Full Text] [Related]

  • 3. [Intervals between hospitalisations in schizophrenia patients under antipsychotics in depot-form versus oral second generation antipsychotics].
    Gutwinski S, Müller P, Koller M.
    Psychiatr Prax; 2007 Sep; 34(6):289-91. PubMed ID: 17806015
    [Abstract] [Full Text] [Related]

  • 4. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies.
    Kane JM.
    J Clin Psychiatry; 2003 Sep; 64 Suppl 16():34-40. PubMed ID: 14680417
    [Abstract] [Full Text] [Related]

  • 5. Choice of maintenance medication for schizophrenia.
    Davis JM, Chen N.
    J Clin Psychiatry; 2003 Sep; 64 Suppl 16():24-33. PubMed ID: 14680416
    [Abstract] [Full Text] [Related]

  • 6. Risks versus benefits of different types of long-acting injectable antipsychotics.
    McEvoy JP.
    J Clin Psychiatry; 2006 Sep; 67 Suppl 5():15-8. PubMed ID: 16822092
    [Abstract] [Full Text] [Related]

  • 7. Comparative efficacy of long-acting depot and oral neuroleptic medications in preventing schizophrenic recidivism.
    Babiker IE.
    J Clin Psychiatry; 1987 Mar; 48(3):94-7. PubMed ID: 2880839
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients.
    Glazer WM, Ereshefsky L.
    J Clin Psychiatry; 1996 Aug; 57(8):337-45. PubMed ID: 8752015
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Is our clinical practice of antipsychotic relapse prevention in schizophrenia really evidence-based].
    Schanda H, Stompe T.
    Neuropsychiatr; 2010 Aug; 24(1):14-26. PubMed ID: 20146916
    [Abstract] [Full Text] [Related]

  • 12. Dose response of prophylactic antipsychotics.
    Davis JM, Kane JM, Marder SR, Brauzer B, Gierl B, Schooler N, Casey DE, Hassan M.
    J Clin Psychiatry; 1993 Mar; 54 Suppl():24-30. PubMed ID: 8097195
    [Abstract] [Full Text] [Related]

  • 13. The attitude of patients towards antipsychotic depot treatment.
    Heres S, Schmitz FS, Leucht S, Pajonk FG.
    Int Clin Psychopharmacol; 2007 Sep; 22(5):275-82. PubMed ID: 17690596
    [Abstract] [Full Text] [Related]

  • 14. Predictors for starting depot administration of risperidone in chronic users of antipsychotics.
    Vehof J, Postma MJ, Bruggeman R, De Jong-Van Den Berg LT, Van Den Berg PB, Stolk RP, Burger H.
    J Clin Psychopharmacol; 2008 Dec; 28(6):625-30. PubMed ID: 19011430
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics.
    Ereshefsky L, Mascarenas CA.
    J Clin Psychiatry; 2003 Dec; 64 Suppl 16():18-23. PubMed ID: 14680415
    [Abstract] [Full Text] [Related]

  • 17. The use of depot neuroleptics: clinical experience in the United States.
    Kane JM.
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):5-12. PubMed ID: 6370987
    [Abstract] [Full Text] [Related]

  • 18. Overview of partial compliance.
    Marder SR.
    J Clin Psychiatry; 2003 May; 64 Suppl 16():3-9. PubMed ID: 14680412
    [Abstract] [Full Text] [Related]

  • 19. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
    Marinis TD, Saleem PT, Glue P, Arnoldussen WJ, Teijeiro R, Lex A, Latif MA, Medori R.
    Pharmacopsychiatry; 2007 Nov; 40(6):257-63. PubMed ID: 18030649
    [Abstract] [Full Text] [Related]

  • 20. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia.
    Bhanji NH, Chouinard G, Margolese HC.
    Eur Neuropsychopharmacol; 2004 Mar; 14(2):87-92. PubMed ID: 15013023
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.